Concierge Choice Physicians (CCP), the nation’s leading full-service concierge medical service provider, announces today that Medical Clinic of Houston (MCH) internal medicine physician Shilka S. Babu, M.D.,
Concierge Choice Physicians, a top provider of full-service concierge medical programs in the United States, has announced that Dr. Daniel W. Schatz, an internal medicine
Pfizer Inc and Astellas Pharma Inc have announced encouraging early results from the Phase 3 EV-303 (KEYNOTE-905) trial. The study evaluated PADCEV (enfortumab vedotin), an
Insights from Vivalink’s survey help sponsors and CROs design trials that improve participation and retention As sponsors increasingly expand clinical trials to include remote participants,
Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical
Breast cancer patients face devastating consequences for access to critical breast cancer care Susan G. Komen, the world’s leading nonprofit breast cancer organization, is
Organon, a global healthcare company with a focus on women’s health, announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in
EXACT Therapeutics, a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial. The trial is a multi-centre, open-label Phase
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Iovance Biotherapeutics, a commercial biotechnology company focused on innovating, developing, and
Integrated solution with self-service capabilities simplifies trial experience for all Medable Inc., a leading provider of clinical development and eCOA technology, announced its next-generation digital
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16
Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1
